| Executive Summary: | NanoVector, Inc. is commercializing the first biologic nanoparticle drug delivery system for the $48B/yr global cancer market. Our breakaway technology will finally provide the highly sought after selective targeting of tumors and intracellular delivery of anti-cancer agents for improved efficacy and fewer unpleasant side effects. The plant virus nanoparticle has evolved over millions of years to have several inherent characteristics essential for a successful nanoparticle delivery system and superior to any chemistry based nanoparticle designed and engineered by humans. |
